Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 3, 2011

View Archived Issues

Frizzled FZD3 receptor expression as a biomarker of CRC and colorectal adenoma

Novel protein kinase inhibitors described at sanofi-aventis

ELGEN-1000-delivered DNA vaccines cleared to enter phase II leukemia trial in U.K.

Genzyme divests diagnostics and pharmaceutical intermediates businesses

Optic nerve sheath CSF flow dynamics as an imaging biomarker of IIH

Scientists generate stable aqueous nanocolloids to improve delivery of anticancer agents

New bombesin BB3 receptor agonist MK-5046 shows preclinical potential to treat obesity

Concert Pharma develops new deuterated GABA(A) receptor modulators

Arena Pharma claims new lysophospholipid S1P1 receptor agonists

Prolia available in Quebec for postmenopausal osteoporosis

Perseid Therapeutics begins phase I trial for CTLA4-Ig program

EMA approves sublingual sildenafil formulation X-Excite for erectile dysfunction

New GPR119 receptor agonists presented

Sinovac Biotech files clinical trial application in China for 23- and 24-valent PPVs

Zymenex's Lamazym advances to phase II in alpha-mannosidosis

Encouraging interim phase II data on Medicago's H5N1 vaccine

Prolor's factor IX-CTP shows promise in model of hemophilia

Isis Pharma begins phase I trial of ISIS-FXIRx for clotting disorders

Enrollment started in Aveo Pharma's phase II tivozanib biomarker trial

Enrollment halted in INSPIRE trial of necitumumab in advanced NSCLC

Temple University divulges new leptin receptor agonists

Sunovion set to launch Latuda in U.S. for schizophrenia

New inhibitors claimed of RAC-alpha serine/threonine-protein kinase phosphorylation

Pegasys/Copegus combination to get priority review in Japan for new indication

Otuska Pharma begins Japanese phase II OCV-101 trial in pancreatic cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 12, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...